Lloyd Carney - Vertex Pharmaceuticals Independent Director

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  Director
Mr. Lloyd A. Carney is Independent Director of the Company
Age: 56  Director Since 2019      
617 341-6100  www.vrtx.com
Carney is the Chairman and Chief Executive Officer of ChaSerg Technology Acquisition Corporationrationration, a technology acquisition company. He was the Chief Executive Officer of Brocade Communications Systems Inc., or Brocade, a global supplier of networking hardware and software, from January 2013 until 2017, when it was acquired by Broadcom. Prior to Brocade, he served as Chief Executive Officer of Xsigo Systems, a cloudbased infrastructure solutions provider, until its acquisition by Oracle. He has also served as the Chief Executive Officer and Chairman of Micromuse Inc., a software solutions provider for business and service assurance, until its acquisition by IBM. Earlier in his career he had held senior leadership roles at Juniper Networks, Inc., Nortel Networks Inc., and Bay Networks, Inc. He currently sits on the board of directors at Visa Inc. and Nuance Communications, Inc

Lloyd Carney Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.3 % which means that it generated profit of $8.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 51.75 % meaning that it created $51.75 on every $100 dollars invested by stockholders.
The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Louise ParentZoetis
2013
Allan ObermanDr Reddys Laboratories Ltd
2019
Rolf ClassonPerrigo Company Plc
2017
Sridar IyengarDr Reddys Laboratories Ltd
2011
Ashok GangulyDr Reddys Laboratories Ltd
2009
Anthony ColesRegeneron Pharmaceuticals
2017
Gary KunklePerrigo Company Plc
2009
Christine PoonRegeneron Pharmaceuticals
2010
Michael BrownRegeneron Pharmaceuticals
1991
Leo PuriDr Reddys Laboratories Ltd
2018
Charles BakerRegeneron Pharmaceuticals
N/A
Paul BisaroZoetis
2015
James KangOrigin Agritech Limited
2010
Prasad MenonDr Reddys Laboratories Ltd
2019
Ellen HoffingPerrigo Company Plc
2008
Gregory NordenZoetis
2013
Arthur RyanRegeneron Pharmaceuticals
2003
Adriana KaraboutisPerrigo Company Plc
2017
Theodore SamuelsPerrigo Company Plc
2017
Michael JandernoaPerrigo Company Plc
2007
Herman MorrisPerrigo Company Plc
1999

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Crypto Portfolio Optimizer Now

   

Crypto Portfolio Optimizer

Optimize portfolio of digital coins and token across multiple currency and exchanges
All  Next Launch Module

Also Currentnly Active

Purchased one share of
few days ago
Traded for 14.25
Purchased one share of
few days ago
Traded for 9.75
Purchased less than 1 share of
few days ago
Traded for 46.8
Also please take a look at World Market Map. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Search macroaxis.com